Last updated July 17, 2026
Key finding
Oral semaglutide 25 mg provided significantly greater weight reduction compared with placebo (9.4% and 7.8%).
This study evaluated the efficacy of once-daily oral semaglutide 25 mg in adults with obesity and type 2 diabetes, finding significant weight reduction compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy of once-daily oral semaglutide 25 mg in adults with obesity and type 2 diabetes, finding significant weight reduction compared to placebo.
The findings suggest that oral semaglutide 25 mg could be an effective treatment option for weight management in adults with obesity and type 2 diabetes. This is particularly relevant as obesity is a major risk factor for diabetes complications, and effective weight loss strategies can improve overall health outcomes.
The study design was non-randomized, which may introduce bias. Sample size and demographic details were not specified. Generalizability to broader populations may be limited.
Published in
Publication details and source links for this paper.
Rune VO, Oscar B, Naveen R, et al. Efficacy of Once-Daily Oral Semaglutide 25 mg in Adults with Obesity and Type 2 Diabetes: A Model-Informed Approach. Diabetes, Obesity & Metabolism. 2026;28(7):5982-5991. doi:10.1111/dom.70769
Participants on oral semaglutide experienced a weight reduction of 9.4% compared to 7.8% in the placebo group.
A greater proportion of participants on semaglutide achieved weight loss of 5% or more compared to placebo.
A greater proportion of participants on semaglutide achieved weight loss of 10% or more compared to placebo.
Nausea was the most common gastrointestinal adverse event reported.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide and Gastrointestinal disorders incidence, Proportion of participants achieving weight loss of 15% or more at 52 weeks, Proportion of participants achieving weight loss of 5% or more at 52 weeks, and 2 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
5
Evidence pairs
377
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Semaglutide → Gastrointestinal disorders incidence
Semaglutide → Gastrointestinal disorders incidence
Semaglutide → Proportion of participants achieving weight loss of 15% or more at 52 weeks
Semaglutide → Proportion of participants achieving weight loss of 15% or more at 52 weeks
Semaglutide → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Semaglutide → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Semaglutide → Weight loss of 10% or more at 52 weeks
Semaglutide → Weight loss of 10% or more at 52 weeks
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Weight change
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may worsen Gastrointestinal Adverse Events or be associated with harm.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Gastrointestinal disorders incidence
EvidenceScore™ Strong | EvidenceScore™ 80.8 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 6 supporting studies and existing graph evidence signals.
Limitations
Semaglutide may worsen Proportion of participants achieving weight loss of 15% or more at 52 weeks or be associated with harm.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Proportion of participants achieving weight loss of 15% or more at 52 weeks
EvidenceScore™ Unknown | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Semaglutide may worsen Proportion of participants achieving weight loss of 5% or more at 52 weeks or be associated with harm.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Proportion of participants achieving weight loss of 5% or more at 52 weeks
EvidenceScore™ Unknown | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
